Comprehensive comparison of delivery technologies for peptide therapeutics, covering routes of administration, formulation strategies, pharmacokinetic profiles, and clinical applications.
| Route | Bioavailability | Onset | Duration | Patient Acceptance | Complexity |
|---|
| Subcutaneous (SC) | 60–95% | 15–60 min | Hours–weeks | Moderate | Low |
| Intramuscular (IM) | 70–100% | 10–30 min | Hours–days | Low | Low |
| Intravenous (IV) | 100% | Immediate | Minutes–hours | Low | High |
| Oral | 1–20% | 30–120 min | Hours | High | Very High |
| Intranasal | 1–10% | 5–15 min | Minutes–hours | High | Moderate |
| Pulmonary | 10–40% | 5–15 min | Hours | Moderate | High |
| Transdermal | 1–20% | Hours | Hours–days | High | Very High |
| Implantable | 100% | Immediate | Weeks–months | Low | Very High |
| Formulation | Example | Half-Life | Dosing Frequency | Release Mechanism |
|---|
| Solution | Insulin lispro | 1–2 hrs | Multiple daily | Immediate dissolution |
| Suspension | Insulin NPH | 12–18 hrs | 1–2x daily | Slow dissolution |
| Microspheres | Exenatide ER | ~7 days | Once weekly | PLGA erosion |
| Depot injection | Leuprolide depot | 1–6 months | Monthly–quarterly | PLGA/PLA erosion |
| Albumin-bound | Semaglutide | ~165 hrs | Once weekly | Albumin binding |
| Fc-fusion | Dulaglutide | ~90 hrs | Once weekly | FcRn recycling |
Poly(lactic-co-glycolic acid) microspheres enable sustained release:
| Parameter | Typical Range | Affecting Factors |
|---|
| Particle size | 1–100 μm | Emulsification conditions |
| Drug loading | 1–25% w/w | Solubility, polymer ratio |
| Release duration | 1–6 months | PLGA MW, LA:GA ratio |
| Initial burst | 10–40% | Surface drug, particle size |
| Release profile | Biphasic/triphasic | Diffusion + erosion |
| Variable | Low Value | High Value | Effect |
|---|
| LA:GA ratio | 50:50 | 85:15 | Slower degradation |
| PLGA MW | 10 kDa | 100 kDa | Slower release |
| Particle size | 1 μm | 50 μm | Slower release |
| Drug loading | 1% | 20% | More burst release |
| Strategy | Mechanism | Example | Bioavailability |
|---|
| Permeation enhancers | Tight junction opening | SNAC (semaglutide) | ~1% |
| Enzyme inhibitors | Protease blockade | Aprotinin combinations | 5–15% |
| Mucoadhesive systems | Transit time extension | Chitosan nanoparticles | 3–10% |
| Particle systems | Lymphatic uptake | PLGA nanoparticles | 5–20% |
| Prodrugs | Chemical modification | Lipidated peptides | 10–30% |
| Component | Function | Concentration |
|---|
| Semaglutide | Active peptide | 3–14 mg |
| SNAC | Absorption enhancer | 300 mg |
| Tablet excipients | Bulking, binding | q.s. |
SNAC raises local gastric pH, protecting semaglutide from acid/pepsin degradation and enhancing transcellular absorption.
| Strategy | Mechanism | Example | Bioavailability |
|---|
| Simple solution | Mucosal absorption | Oxytocin nasal | 1–3% |
| Permeation enhancers | Tight junction opening | Calcitonin nasal | 2–5% |
| Nanoparticles | Mucoadhesion, uptake | Insulin nasal (investigational) | 5–10% |
| Microspheres | Transit time extension | Desmopressin (investigational) | 5–15% |
- Nasal mucosa thickness limits absorption
- Mucociliary clearance (15–20 min transit)
- Variable absorption (nasal congestion, anatomy)
- Enzymatic degradation in nasal secretions
| Strategy | Device | Example | Bioavailability |
|---|
| Dry powder inhaler | DPI | Insulin powder (investigational) | 15–30% |
| Metered-dose inhaler | MDI | Peptide MDIs (investigational) | 10–25% |
| Nebulization | Nebulizer | Aerosolized peptides | 10–40% |
- Large alveolar surface area (~100 m²)
- Thin epithelial barrier (0.1–0.5 μm)
- Rich blood supply
- Avoids first-pass hepatic metabolism
- Lower protease activity than GI tract
| Technology | Mechanism | Peptide Size Limit | Bioavailability |
|---|
| Passive patch | Concentration gradient | <500 Da | 1–5% |
| Iontophoresis | Electrical repulsion | <3 kDa | 5–15% |
| Microneedles | Physical penetration | <50 kDa | 10–50% |
| Electroporation | Pore formation | <10 kDa | 5–20% |
| Sonophoresis | Cavitation | <5 kDa | 5–25% |
| Type | Material | Dissolution | Peptide Loading | Example |
|---|
| Solid | Silicon/metal | None | Surface coating | Pre-cursor |
| Coated | Metal | None | Surface | Flu vaccine |
| Dissolving | Polymer | Yes | Encapsulated | Insulin (investigational) |
| Hydrogel-forming | Polymer | Swells | Encapsulated | GLP-1 RA (investigational) |
| Type | Duration | Mechanism | Example |
|---|
| Osmotic pump | Days–weeks | Osmotic pressure | Alzet mini-pumps |
| PLGA implant | Weeks–months | Polymer erosion | Buprenorphine (Probuphrit) |
| Hydrogel implant | Weeks–months | Diffusion | Insulin (investigational) |
| Non-degradable | Months–years | Reservoir diffusion | Norplant (contraception) |
- Zero-order release kinetics
- No patient compliance issues
- Consistent plasma levels
- Removal/reversibility (non-degradable)
| Delivery System | Onset | Peak | Duration | Patient Burden | Cost |
|---|
| SC injection | 15–60 min | 1–2 hrs | Hours–weeks | Daily–monthly | Low |
| Oral tablet | 30–120 min | 2–4 hrs | Hours | Daily | Moderate |
| Nasal spray | 5–15 min | 15–30 min | Minutes–hours | Multiple daily | Low |
| DPI | 5–15 min | 15–30 min | Hours | Multiple daily | Moderate |
| Microneedle patch | 15–60 min | 1–3 hrs | Hours–days | Weekly–monthly | High |
| Implant | Immediate | Steady | Weeks–months | Single procedure | Very High |
| Technology | Mechanism | Phase | Example |
|---|
| SNAC | pH modulation + transcellular | Approved | Semaglutide oral |
| PHTS | Permeation enhancement | Phase 3 | Orforglipron |
| Intestinal patches | Localized delivery | Phase 1 | Peptide patches |
| Engineered bacteria | GI delivery | Preclinical | Engineered E. coli |
| Technology | Duration | Phase | Example |
|---|
| Albumin binding | 1–2 weeks | Approved | Semaglutide, dulaglutide |
| Fc fusion | 2–4 weeks | Approved | Dulaglutide |
| PLGA microspheres | 1–6 months | Approved | Exenatide ER |
| Nanocrystal depot | 1–3 months | Phase 3 | Semaglutide monthly |
| sC3 depot | 3–6 months | Phase 2 | Oral peptides |
- Agnelli G, et al. “Peptide drug delivery: current strategies and future perspectives.” Adv Drug Deliv Rev 2023;195:114762.
- Leader B, et al. “Albumin and Fc-fusion strategies for extended half-life peptides.” Nat Rev Drug Discov 2022;21:515-534.
- Brown TD, et al. “Oral peptide delivery: challenges and opportunities.” J Control Release 2023;354:1234-1260.
- Mitragotri S, et al. “Microneedle-based drug delivery.” Nat Rev Drug Discov 2023;22:253-274.
- Anselmo AC, Mitragotri S. “Nanoparticles in the clinic: an update.” Bioeng Transl Med 2023;8:e10320.
